While clinical developments are progressing, the sharp revenue decline raises concerns about commercial sustainability. Traders should monitor upcoming interim data from the FG-3246 trial in 2026 as a key value driver, but near-term fundamentals remain weak.
Price Chart
Executive Summary
Kyntra Bio reported a significant year-over-year decline in revenue and wider net losses from continuing operations for Q4 and full-year 2025, despite positive clinical updates on its FG-3246 program and submission of a Phase 3 protocol for roxadustat. The company maintains a strong cash position of $109.4 million, funding operations into 2028.
Key Financial Metrics
Key Facts
- Total revenue from continuing operations for full-year 2025 was $6.4 million, down from $29.6 million in 2024 — a 78.4% year-over-year decline.
- Net loss from continuing operations for full-year 2025 was $58.2 million, compared to $153.1 million in 2024 (improved due to discontinued operations, not core business performance).
- Q4 2025 revenue was $1.3 million vs. $3.1 million in Q4 2024.
- Cash, cash equivalents, investments, and accounts receivable totaled $109.4 million as of December 31, 2025, providing runway into 2028.
- Phase 2 monotherapy trial of FG-3246 in mCRPC is enrolling with interim analysis expected in 2H 2026.
- Roxadustat Phase 3 protocol for LR-MDS submitted to FDA; trial planned for 2H 2026.
Financial Impact
Revenue declined by 78.4% YoY ($23.2 million drop) from 2024 to 2025, driven by lower drug product revenue. Core business (continuing operations) remains unprofitable with $58.2M net loss.
Risk Factors
- Continued decline in core revenue streams with no clear near-term reversal.
- High cash burn relative to shrinking revenue base despite improved losses.
- Clinical trial delays or negative results could severely impact valuation given limited revenue diversification.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256693 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 3 | $6.13 $5.57 | ▼ −9.22% | ▼ −8.24% | $4.50 (−26.59%) |
Oct 6, 2026 21d ago | 8-K | $6.13 $5.57 | ▲ +9.22% | ▲ +8.24% | $4.50 (+26.59%) |
Oct 1, 2026 26d ago | 8-K | $6.50 $5.96 | ▼ −8.31% | ▼ −9.61% | $4.50 (−30.77%) |
Jun 9, 2026 20w ago | 8-K | $6.69 $6.91 | ▲ +3.29% | ▼ −0.14% | $4.50 (−32.74%) |
May 11, 2026 24w ago | Press Release | $7.23 $6.83 | ▼ −5.47% | ▼ −5.54% | $4.50 (−37.72%) |
Mar 16, 2026 32w ago | Press Release | $7.37 $6.75 | ▲ +8.41% | ▲ +5.76% | $4.50 (+38.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers